argenx registers Phase 2 trial of ARGX-121 in IgA nephropathy
A new "Verdant" study will test ARGX-121 against placebo in adults with primary IgA nephropathy, with enrollment not yet open.
This week's item covers a single new registration for argenx.
- A Phase 2, multicenter, randomized, placebo-controlled study called "Verdant" (NCT07773727) will evaluate the efficacy, safety, and tolerability of subcutaneous ARGX-121 in adult participants with primary IgA nephropathy, sponsored by argenx.1 The trial is listed as not yet recruiting, with an estimated start date of October 15, 2026, and plans to enroll 120 participants.1 The main goal is measured through a UPCR-based proteinuria endpoint at week 24, per the study record.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.